At today's extraordinary general meeting at Bioservo, the following previously published decision was made: To issue warrants for the establishment of an employee stock option program. The increase in Bioservo's share capital will be SEK 77,122 at full subscription and full exercise of the warrants. This increase corresponds to a dilution of shareholders' holdings by approximately 4.3 percent, based on the existing number of outstanding shares in Bioservo. For detailed terms regarding the decision at the extraordinary general meeting, please refer to the full proposal available on the company's website:

About Bioservo Technologies AB 

Bioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company has a leading global position within soft exoskeleton technology, wearable non-invasive products, for people in need of extra power to support the body's endurance and performance, or for people with reduced muscular strength.

After many years of research and development, Bioservo Technologies now focus on the commercialization of its products and patented technologies. The developed gloves are well suited for both rehabilitation within health and medical care and preventively for professionals in the industry. The company has signed strategic cooperation agreements with several multinational companies within e.g. the automobile, aircraft as well as the construction and infrastructure industry.

Bioservo Technologies was founded in 2006 through a collaboration between researchers at the Royal Institute of Technology and doctors at Karolinska University Hospital in Stockholm. Bioservo Technologies is a Swedish public company with headquarters and operations in Kista, north of Stockholm. FNCA Sweden AB is the company's Certified Adviser on Nasdaq First North.

For more information, please visit

Bioservo Technologies AB contact

Anders Lundmark                                                     


Tel.: +46 (0)70 447 52 25

Powered by WPeMatico